PMGC Holdings (ELAB) Operating Income (2022 - 2026)
PMGC Holdings (ELAB) posted Operating Income of -$3.3 million for Q1 2026, down 35.07% sequentially from -$2.5 million in Q4 2025, and down 2835.45% YoY from $121851.0 in Q1 2025.
PMGC Holdings (ELAB) Operating Income (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Operating Income for 5 years, with the latest figure at -$3.3 million in Q1 2026.
- Quarterly Operating Income fell 2835.45% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 12981.75% YoY) and the FY2025 annual result came in at -$6.9 million, down 268.72% from the prior year.
- Operating Income slipped to -$3.3 million in Q1 2026 per ELAB's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Operating Income peaked at $1.1 billion in Q4 2022 and troughed at -$471.8 million in Q3 2022.
- A 5-year average of $45.0 million and a median of -$1.1 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income soared 298.48% in 2024, then sank 2835.45% in 2026.
- Over 5 years, Operating Income stood at $1.1 billion in 2022, then sank by 100.1% to -$1.1 million in 2023, then jumped by 298.48% to $2.1 million in 2024, then slumped by 215.03% to -$2.5 million in 2025, then plunged by 35.07% to -$3.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$3.3 million, -$2.5 million, and -$2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | -3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.33 Mn |
| Dec 31, 2025 | -2.47 Mn |
| Sep 30, 2025 | -2.20 Mn |
| Mar 31, 2025 | 121,851.00 |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | -919,837.00 |
| Jun 30, 2024 | -1.41 Mn |
| Mar 31, 2024 | -1.68 Mn |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -785,551.00 |
| Jun 30, 2023 | -1.05 Mn |
| Mar 31, 2023 | -846,389.00 |
| Dec 31, 2022 | 1.12 Bn |
| Sep 30, 2022 | -471.84 Mn |